Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M0WJ
|
||||
| Former ID |
DIB012571
|
||||
| Drug Name |
Liposomal encapsulated doxorubicin (LED)
|
||||
| Indication | Breast cancer; Prostate cancer [ICD9: 174, 175, 185; ICD10:C50, C61] | Phase 2 | [1] | ||
| Company |
NeoPharm
|
||||
| Target and Pathway | |||||
| Target(s) | DNA topoisomerase II | Target Info | Modulator | [2] | |
| References | |||||
| REF 1 | Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.